HomeAI · summaries
Storia in 6 fonti
FDA approves Jazz's Ziihera in frontline gastric cancer
Jazz's Ziihera wins FDA nod for frontline HER2+ gastric cancer, clearing use with chemo, with or without BeOne's Tevimbra.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Ziihera combinations for gastroesophageal adenocarcinoma
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal…
- ·
biopharmadive.com
New Jazz cancer drug approval could drive blockbuster sales
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
